Phase II study of weekly amrubicin for refractory or relapsed non-small cell lung cancer

Chiyoe Kitagawa, Masahiro Iwasaku, Yoshihito Kogure, Masahiko Ando, Hiroshige Yoshioka, Akihiro Nishiyama, Naoki Watanabe, Kei Kunimasa, Kazuya Tsubouchi, Saori Oka, Hideo Saka

Research output: Contribution to journalArticlepeer-review

2 Citations (Scopus)


Background: Amrubicin is usually administered on days 1-3 every 3 weeks by intravenous infusion. However, it causes severe hematological toxicity, especially febrile neutropenia. It was reported that weekly administration confers higher dose intensity, less severe adverse events, and anti-tumor activity that is as effective as that of treatment with a conventional schedule. Patients and Methods: Weekly amrubicin was administered at a dose of 60 mg/m2 on days 1 and 8 every 3 weeks. The primary endpoint was overall response rate. Results: A total of 33 patients were enrolled. The overall response rate was 6.1% (95% confidence interval(CI)=0.7-20.2%) and the disease control rate after 2 months was 51.5%. The median progression-free survival was 2.93 months. Febrile neutropenia was observed in only two patients. Conclusion: The primary endpoint was not met in this study. However, weekly amrubicin achieved a high disease control rate and good tolerability.

Original languageEnglish
Pages (from-to)163-166
Number of pages4
JournalIn Vivo
Issue number1
Publication statusPublished - Jan 1 2019
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • General Biochemistry,Genetics and Molecular Biology
  • Cancer Research
  • Pharmacology


Dive into the research topics of 'Phase II study of weekly amrubicin for refractory or relapsed non-small cell lung cancer'. Together they form a unique fingerprint.

Cite this